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on quality of sleep, and one in five (22%) reported that an event highly impacted their 
social life. Hypoglycaemic events did not severely effect paid work (n= 16/15), with 
19%/7% (N/D) of respondents reporting arriving at work late or leaving early, and 
13%/7% (N/D) missing ≥ 1 full working day. ConClusions: Nocturnal and daytime 
non-severe hypoglycaemic events have an impact upon patients’ health-related 
quality of life and diabetes management in Colombia.
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objeCtives: While bariatric surgery is being increasingly employed as a cost-
effective option for treatment of obesity, it has not yet realized its full potential. 
Patient participation in the full treatment cycle is key to adoption and outcomes. 
To that end, the objectives of this study were three-fold: 1) Determine how 
patients are expected to share the burden of bariatric surgery treatment efficacy, 
2) Characterize factors that influence patient willingness to adopt and pay, and 3) 
Identify approaches to improve patient outcomes. Methods: Global clinical guide-
lines and HTAs published from 2008-2013 were analyzed. These results were collated 
with a survey of 2,784 patients across 12 countries, representing major markets in 
the Americas, Europe, Middle East, and Asia. Surveyed patients were in 26 – 50 age-
groups and with BMI in the 34.3 – 43.4 kg/m2 range. It evaluated patients’ perception 
of barriers in terms of cost and safety, and motivators to adopt surgical procedures 
for treatment of obesity. Results: Clinical guidelines and HTAs recommended 
that pre-treatment patients comply with weight-loss regimens, and post-treatment 
adhere to severe dietary restrictions, life-style changes, and life-long follow-up. 
The survey indicated that while patient age, income level, and physicians’ opinion 
were strong indicators of patients’ likelihood of considering surgery, BMI was not. 
Importantly, three significant barriers to adoption were identified: a) lack of under-
standing of safety and efficacy, b) the perceived out-of-pocket cost of treatment, and 
c) the extent of sustainable life style changes expected of patients. ConClusions: 
Although bariatric surgery is considered potentially clinically- and cost-effective, 
patient willingness to undertake surgery indicates a chasm between perception 
and reality. To aid in bridging that gap, findings suggested that three key issues 
must be addressed: a) improve patient education and physician engagement, b) 
expand the evidence base to demonstrate long-term clinical benefits of surgery, 
including metabolically-related risk factors, and c) demonstrate economic benefits 
to price-sensitive patients.
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objeCtives: To evaluate the impact of an employer-based copayment waiver for 
diabetes care on medication adherence, diabetes care and spending among enrollees 
with diabetes and within subgroups of patients who had low use, moderate use, 
and adherent use of diabetes medications prior to start of the benefit. Methods: 
Enrollees in eligible health plans with diabetes were automatically enrolled in a 
copayment waiver ($0 copay) benefit beginning January 2011 for diabetes, cardio-
vascular, and lipid lowering medications, screenings, diabetes supplies, and diabe-
tes related office visits. The study included 444 enrollees with diabetes who were 
propensity score matched to a comparison group of patients with diabetes within 
nine similar firms without these benefits (N= 444 comparison). An enrollee-calendar 
quarter panel data set was constructed from January 2009-June 2012. Impact was 
measured as the change in outcomes post-enrollment in the copayment waiver 
group relative to the change in the comparison group (difference-in-differences). 
Percent of Days Covered (PDC) with diabetes medications prior to 2011 was used to 
classify patients: low adherence (PDC< 20%, N= 127 treatment, N= 127 comparison), 
moderate adherence (20%≤ PDC< 80%, N= 115 treatment, N= 115 comparison), and 
adherent (PDC≥ 80%, N= 202 treatment, N= 202 comparison). Results: In the full 
sample, PDC for oral diabetes medications increased 8.7% points to 54.2% (13.3% 
increase, P< 0.01), the number of outpatient office visits for diabetes increased 
10.8% (P= 0.03) and prescription fills of diabetes supplies increased 29.1% (P< 0.01). 
Among enrollees with low prior adherence, PDC increased from 10.5% to 20.9% 
(95% increase, P< 0.01). In the full sample, total spending (medical plus prescription 
drug) did not change (P= 0.76). ConClusions: Results through the first eighteen 
months show that waiving copayments for patients with diabetes can improve 
adherence to diabetes medication, office visits and supplies with a minimal impact 
on spending. Large increases in adherence occurred for patients with the low levels 
of pre-program adherence.
PDb120
retrosPective coHort analysis of tHe Patterns anD PreDictors of 
metformin treatment cHange in a meDicare aDvantage Patient 
PoPUlation from a large national HealtH Plan
Hazel-Fernandez L1, Xu Y.2, Moretz C.1, Meah Y.3, Baltz J.3, Lian J.4, Bouchard J.R.5
1Comprehensive Health Insights, Humana, Miramar, FL, USA, 2Humana, Inc., Louisville, KY, USA, 
3Humana Inc., Louisville, KY, USA, 4Novo Nordisk Inc., Princeton, NJ, USA, 5Novo Nordisk Inc., 
Plainsboro, NJ, USA
objeCtives: No consensus exists among the ADA and the AACE guidelines 
regarding therapy intensification for patients with type 2 diabetes mellitus (T2DM) 
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objeCtives: To study the effect of nocturnal and daytime non-severe hypoglycae-
mic events on people with diabetes in Singapore. Methods: People with diabe-
tes from five countries, including Singapore, who had experienced a non-severe 
hypoglycaemic event in the 4 weeks prior to the survey were eligible. Both surveys 
were conducted face to face; all information, including hypoglycaemic events, was 
self-reported. Results: In the Singaporean cohort, 76 people responded (50 for 
the nocturnal survey [N]; 51 for the daytime survey [D]). Mean age was 54 years/56 
years (N/D), mean weight was 63.2 kg/68.3 kg (N/D), 48%/49% (N/D) were male, 
and 70%/80% (N/D) had type 2 diabetes. Among respondents with type 2 diabe-
tes, 11%/10% (N/D) received insulin and 100%/100% (N/D) received oral medication. 
Almost half of respondents had diabetes-related complications (46%/49% [N/D]), 
and 16%/18% (N/D) experienced hypoglycaemia at least once/week. When asked 
about hypoglycaemia awareness, 14%/14% (N/D) reported only noticing they were 
hypoglycaemic during routine blood glucose checks, while 8%/16% (N/D) were gener-
ally unaware of an event. After a hypoglycaemic event, 12%/20% contacted a health 
care professional and, in the following week, used on average 1.1/2.1 (N/D) extra 
blood glucose strips. Following a nocturnal event, mean time to return to sleep was 
63 minutes; 24% reported difficulty returning to sleep after the event, almost two 
thirds (62%) felt tired and/or fatigued the next day, and 22% reported high level of 
fear of a future event. In the daytime survey, the most common measures taken 
in order to avoid hypoglycaemia were defensive snacking and avoiding exercise. 
Respondents reported spending most time worrying about feeling lightheaded/
dizzy, having an event while alone, and passing out in public. ConClusions: In 
Singapore, hypoglycaemic events impact health care utilisation and daily routines 
for people with diabetes. Treatment strategies to decrease hypoglycaemia could 
offer substantial benefits to people with diabetes.
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objeCtives: To study the effect of nocturnal and daytime non-severe hypoglycae-
mic events on the utilisation of health care services and patient quality of life in 
Mexico. Methods: People with diabetes from six different countries who had expe-
rienced a self-reported non-severe hypoglycaemic event in the past 4 weeks were 
eligible to take part in a nocturnal (N) and/or daytime (D) hypoglycaemia survey. In 
the Mexican cohort, 77 people responded (50 for the nocturnal survey; 50 for the day-
time survey). The surveys were conducted either face to face or online. Results: In 
the Mexican subgroup, 82%/80% (N/D) of respondents had type 2 diabetes, 38%/42% 
(N/D) were male, mean age was 52 years/53 years (N/D), and mean weight was 74.4 
kg/75.6 kg (N/D). Respondents received treatment with insulin (32%/38% [N/D]), oral 
medication (95%/95% [N/D]) and/or diet and exercise (49%/58% [N/D]), and 70%/76% 
considered themselves in good health. Non-severe hypoglycaemic episodes were 
experienced at least once weekly by 34%/44% (N/D) and at least once a month 
by 76%/68% (N/D) of respondents. After a hypoglycaemic event, 41%/16% (N/D) of 
respondents decreased their insulin dose, 50%/58% contacted a health care profes-
sional, and, in the following week, used on average 2/5 (N/D) extra blood glucose 
strips. Almost half of respondents reported a high level of fear of hypoglycaemic 
events (46%/46% [N/D]). Following a nocturnal hypoglycaemic event, mean time to 
return to sleep was 89 minutes, 11% did not go back to sleep at all, and 38% reported 
the nocturnal event had a high impact on their quality of sleep. Of respondents who 
worked for pay (n= 23/21), 30%/67% (N/D) went to work late or left early, and 13%/24% 
(N/D) missed ≥ 1 full working day. ConClusions: In Mexico, nocturnal and daytime 
non-severe hypoglycaemic events severely impact quality of life, quality of sleep 
and productivity in people with diabetes.
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objeCtives: To study the effect of nocturnal and daytime non-severe hypoglycae-
mic events on the utilisation of health care services and health-related quality of life 
in people with diabetes in Colombia. Methods: People with diabetes from five dif-
ferent countries who had experienced a non-severe hypoglycaemic event in the past 
4 weeks were asked to take part in a nocturnal (N) and/or daytime (D) hypoglycaemia 
survey. In the Colombian subgroup, 83 people responded (50 respondents for the 
nocturnal survey; 50 for the daytime survey). Both surveys were conducted face-to-
face. All information, including hypoglycaemic events, was self-reported. Results: 
In the Colombian cohort, respondents’ mean age was 58 years/54 years (N/D), mean 
weight was 64.3 kg/65.5 kg (N/D), 36%/38% (N/D) were male, 76%/76% (N/D) had type 
2 diabetes, and all received treatment with insulin (100%/100% [N/D]). Although 
78%/82% (N/D) of respondents considered themselves in good health, almost half 
had diabetes-related complications (48%/54% [N/D]). Non-severe hypoglycaemic 
episodes were experienced at least once weekly by 16%/20% (N/D) and at least once 
a month by 70%/70% (N/D). After a hypoglycaemic event, 0%/24% (N/D) decreased 
their insulin dose, 32%/40% contacted a health care professional, and, in the follow-
ing week, they used on average 5/6 (N/D) extra blood glucose strips. The majority 
of respondents reported a high level of fear of nocturnal hypoglycaemic events 
(60%/36% [N/D]). One third (32%) reported that a nocturnal event had a high impact 
